{"id": "346486", "url": "https://fevir.net/resources/Group/346486", "meta": {"versionId": "5", "lastUpdated": "2026-01-26T16:43:36.602Z"}, "name": "CTIS2024_516402_32_00_Eligibility_Criteria", "title": "CTIS2024-516402-32-00 Eligibility Criteria", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper, MD, MSPH"}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as", "valueMarkdown": "CTIS2024-516402-32-00 Eligibility Criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 346486. Revised 2026-01-26. Available at: https://fevir.net/resources/Group/346486. Computable resource at: https://fevir.net/resources/Group/346486#json."}], "publisher": "Computable Publishing LLC", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "346486", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "CTIS2024-516402-32-00 Eligibility Criteria", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "membership": "conceptual", "resourceType": "Group", "characteristic": [{"id": "Inclusion-1", "code": {"text": "Eligibility Criterion"}, "exclude": false, "valueCodeableConcept": {"text": "Age \u2265 18 years", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "\u00c2ge \u2265 18 ans"}]}]}}}, {"id": "Inclusion-2", "code": {"text": "Eligibility Criterion"}, "exclude": false, "valueCodeableConcept": {"text": "Hospitalization forHE-aHUS within prior 10 days: o Presume acute renal failure (renal replacement therapy or serum creatinine \u2265 354\u03bcM). o Mechanical hemolysis including: anemia, thrombopenia, and: low haptoglobin (1,5UNL), or presence of schistocytes o Severe hypertension with systolic blood pressure >180mmHg and/or diastolic blood pressure>110mmHg o Target organ damage, including neurological involvement (notably hypertensive encephalopathy, headache, confusion, nausea, posterior reversible encephalopathy syndrome), or cardiovascular involvement (notably acute left ventricular failure, acute pulmonary edema, acute cardiac ischemia, chest pain, dyspnea, palpitations), or ophtalmological involvement (notably ischemic retinopathy or blurred vision)", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Hospitalisation pour un SHUa-HE dans les 10 jours pr\u00e9c\u00e9dents :\no Pr\u00e9somption d'insuffisance r\u00e9nale aigu\u00eb (traitement de substitution r\u00e9nale ou taux de cr\u00e9atinine s\u00e9rique \u2265  354\u00b5M \no H\u00e9molyse m\u00e9canique comprenant : an\u00e9mie, thrombop\u00e9nie, et : haptoglobine basse (1,5UNL), ou pr\u00e9sence de schisocytes\no Hypertension s\u00e9v\u00e8re avec une pression art\u00e9rielle systolique >180mmHg et/ou une pression art\u00e9rielle diastolique>110mmHg\no Atteinte des organes cibles, y compris atteinte neurologique (notamment enc\u00e9phalopathie hypertensive, c\u00e9phal\u00e9es, confusion, naus\u00e9es, syndrome d'enc\u00e9phalopathie r\u00e9versible post\u00e9rieure), ou atteinte cardiovasculaire (notamment insuffisance ventriculaire gauche aigu\u00eb, \u0153d\u00e8me pulmonaire aigu, isch\u00e9mie cardiaque aigu\u00eb, douleurs thoraciques, dyspn\u00e9e, palpitations), ou atteinte ophtalmologique (notamment r\u00e9tinopathie isch\u00e9mique ou vision trouble)."}]}]}}}, {"id": "Inclusion-3", "code": {"text": "Eligibility Criterion"}, "exclude": false, "valueCodeableConcept": {"text": "For women of childbearing potential: Effective contraception during the study and for at least 5 months after the last dose of treatment with eculizumab", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Pour les femmes en mesure de procr\u00e9er : Contraception efficace durant la recherche et au moins jusqu\u2019\u00e0 5 mois apr\u00e8s la derni\u00e8re administration d\u2019\u00e9culizumab"}]}]}}}, {"id": "Inclusion-4", "code": {"text": "Eligibility Criterion"}, "exclude": false, "valueCodeableConcept": {"text": "Subject affiliated to a social security regimen", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Sujet affili\u00e9 \u00e0 un r\u00e9gime de s\u00e9curit\u00e9 sociale"}]}]}}}, {"id": "Inclusion-5", "code": {"text": "Eligibility Criterion"}, "exclude": false, "valueCodeableConcept": {"text": "Subject having signed written informed consent", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Sujet ayant sign\u00e9 un consentement \u00e9clair\u00e9 \u00e9crit"}]}]}}}, {"id": "Exclusion-1", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "Atrophic kidneys with maximum length<8cm on recent (<1 month) renal ultrasound, CT scan, or renal MRI", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Reins atrophi\u00e9s dont la longueur maximale est inf\u00e9rieure \u00e0 8 cm sur une \u00e9chographie r\u00e9nale, une tomodensitom\u00e9trie ou une IRM r\u00e9nale r\u00e9cente (<1 mois)"}]}]}}}, {"id": "Exclusion-10", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "Contra-indication to eculizumab or renin angiotensin system blockers", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Contre-indication \u00e0 l'\u00e9culizumab ou aux bloqueurs du syst\u00e8me r\u00e9nine angiotensine."}]}]}}}, {"id": "Exclusion-11", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "Solid organ or haematopoietic transplant", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Greffe d'organe solide ou h\u00e9matopo\u00ef\u00e9tique"}]}]}}}, {"id": "Exclusion-12", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "History (<1year) of active cancer or exposition to drugs associated with aHUS (< 3 months)", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Ant\u00e9c\u00e9dents (<1 an) de cancer actif ou d'exposition \u00e0 des m\u00e9dicaments associ\u00e9s au SHUa (< 3 mois)"}]}]}}}, {"id": "Exclusion-13", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "Severe cognitive or psychiatric disorders, patients unable to give an informed consent", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Troubles cognitifs ou psychiatriques graves, patients incapables de donner un consentement \u00e9clair\u00e9."}]}]}}}, {"id": "Exclusion-14", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "PCR SARS-CoV2 positive", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "PCR SARS-CoV2 positive"}]}]}}}, {"id": "Exclusion-15", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "Pregnant or breastfeeding woman or ineffective contraception", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Femme enceinte ou allaitante ou contraception inefficace"}]}]}}}, {"id": "Exclusion-16", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "Persons deprived of their liberty by judicial or administrative decision", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Personnes priv\u00e9es de leur libert\u00e9 par d\u00e9cision judiciaire ou administrative"}]}]}}}, {"id": "Exclusion-17", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "Persons under legal protection (guardianship, curatorship)", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Personnes sous protection juridique (tutelle, curatelle)"}]}]}}}, {"id": "Exclusion-18", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Participation \u00e0 une autre \u00e9tude interventionnelle impliquant la personne humaine ou \u00eatre dans la p\u00e9riode d'exclusion \u00e0 la fin d'une pr\u00e9c\u00e9dente \u00e9tude impliquant la personne humaine."}]}]}}}, {"id": "Exclusion-2", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "High clinical suspicion of Complement-mediated aHUS (including familial history of aHUS)", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Forte suspicion clinique de SHUa m\u00e9di\u00e9 par le compl\u00e9ment (y compris ant\u00e9c\u00e9dents familiaux de SHUa)."}]}]}}}, {"id": "Exclusion-3", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "High clinical suspicion of typical HUS (including Shiga Toxin-producing E. Coli infection) or Thrombotic thrombocytopenic purpura", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Forte suspicion clinique de SHU typique (y compris une infection \u00e0 E. Coli producteur deshigatoxine) ou de purpura thrombocytop\u00e9nique thrombotique."}]}]}}}, {"id": "Exclusion-4", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "High clinical suspicion of secondary HUS related to autoimmune disease (including lupus, scleroderma, antiphospholipid syndrome, ANCA vasculitis), or C3 glomerulopathy.", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Forte suspicion clinique de SHU secondaire li\u00e9 \u00e0 une maladie auto-immune (y compris lupus, scl\u00e9rodermie, syndrome des antiphospholipides, vascularite \u00e0 ANCA), ou une glom\u00e9rulopathie \u00e0 C3."}]}]}}}, {"id": "Exclusion-5", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "High clinical suspicion of recent hemorrhagic or ischemic stroke", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Forte suspicion clinique d'un accident vasculaire c\u00e9r\u00e9bral h\u00e9morragique ou isch\u00e9mique r\u00e9cent."}]}]}}}, {"id": "Exclusion-6", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "ADAMTS 13<10%, HIV or HCV infection, positivity of 2 markers among: anticardiolipin IgG/antiBeta2 GP1 IgG/lupus anticoagulant, positivity of ANCA (ELISA PR3 or MPO)", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "ADAMTS 13<10%, infection par le VIH ou le VHC, positivit\u00e9 de 2 marqueurs parmi : IgG anticardiolipine/ IgG antiBeta2 GP1/ anticoagulant lupique, positivit\u00e9 des ANCA (ELISA PR3 ou MPO)."}]}]}}}, {"id": "Exclusion-7", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "Active infection", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Infection active"}]}]}}}, {"id": "Exclusion-8", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "Subjects with unresolved Neisseria meningitidis infection", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Patients avec une infection \u00e0 Neisseria meningitidis non r\u00e9solue"}]}]}}}, {"id": "Exclusion-9", "code": {"text": "Eligibility Criterion"}, "exclude": true, "valueCodeableConcept": {"text": "Subjects refusing Neisseria meningitidis vaccination or refusing antibioprophylaxis with oracillin (In case of penicillin allergy, antibioprophylaxis with macrolide couldbeproposed according to ANSM recommendations (azithromycin or roxithromycin))", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Patients refusants la vaccination contre Neisseria meningitidis   ou refusants une antibioprophylaxie par oracilline (En cas d'allergie \u00e0 la p\u00e9nicilline, une antibioprophylaxie par macrolide pourra \u00eatre propos\u00e9e selon les recommandations de l'ANSM (azithromycine ou roxithromycine))."}]}]}}}], "combinationMethod": "all-of", "description": "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide."}